Introduction
On 24 July 2026, The Stock Exchange of Hong Kong Limited (“HKEX”) published its consultation conclusions on enhancing the competitiveness of Hong Kong’s listing framework, confirming amendments to the related Rules Governing the Listing of Securities on the HKEX (the “Listing Rules”). The new Listing Rules took effect immediately upon publication.
The new amendments lowered the general threshold for Weighted Voting Rights (“WVR”) structured companies to be listed in Hong Kong, optimised various measures for issuers listed overseas and embraced looser initial listing requirements and listing arrangements. The relevant changes aim to enhance the flexibility and diversity of Hong Kong’s listing regime, whilst maintaining robust corporate governance and investor protection.
Major changes are stated below:
A. Weighted Voting Rights
The revised Listing Rules reduced the financial eligibility thresholds and relaxed restrictions on voting and ownership structures, providing greater flexibility for large-scale issuers to retain founder control.
| Previous Requirements | New Amendments | |
| Financial Eligibility | WVR companies are eligible to list if (a) their market capitalisation is at least HK$40 billion; or (b) their market capitalisation is at least HK$10 billion and revenue for the most recent audited financial year is at least HK$1 billion. | Lowered Thresholds: WVR companies are eligible for listing if (a) their market capitalisation is at least HK$20 billion; or (b) their market capitalisation is at least HK$6 billion, and revenue for the most recent audited financial year is at least HK$600 million. |
| Voting power and minimum economic interest at listing | 1.Weighted voting ratio 10:1 WVR ratio cap 2.Minimum collective economic interest WVR beneficiaries to beneficially and collectively own at least 10% of the underlying economic interest in the applicant’s total issued share capital at the time of its initial listing | 1. Allowing higher WVR ratio cap of 20:1 for applicants with a market capitalisation of at least HK$40 billion at the time of listing. 2. WVR beneficiaries to hold at least 5% of the underlying economic interest, provided that the underlying holding represents an aggregate economic value of at least HK$4 billion at listing. |
Innovativeness
Historically, demonstrating that an applicant qualified as an “innovative company” presented subjective hurdles, particularly for tech-enabled consumer businesses or companies not seeking to list under specialist chapters (such as Chapters 18A or 18C). The revised rules established two distinct pathways (“Route A”or “Route B”).
Route A (New technology)
The applicant adopts technologies that are either novel, in themselves, or essential to the novelty of its core business.
Route B (New Business Model)
The applicant’s success is attributable to the application, to its core business, of a new business model that may not necessarily be enabled by technology. Where such a business model is enabled by technology, that technology does not have to be novel or essential to the novelty of the issuer’s core business.
| An applicant under Route A would be expected to possess more than one of the following innovative characteristics:(i) Research and Development (“R&D”): R&D is a significant contributor to the applicant’s expected value and constitutes a major activity and expense. (ii) Intellectual Property: Providing detailed explanation on how its IP enabled it to achieve business success. (iii) Outsized Market Cap Characteristic: Having an outsized market capitalisation/intangible asset value relative to its tangible asset value. | An applicant under Route B would normally be expected to possess all of the following new innovative characteristics:(i) Compound Annual Growth Rate (CAGR) Growth: Applicant must have a CAGR in revenue of at least 30% over the track record period. (ii) Industry Position: Must demonstrate that it holds a relatively prominent position in its industry. |
Presumption of “Innovative” status and clarification of “Sophisticated Investor”
Previously, only Biotech Companies or Specialist Technology Companies seeking to list under Chapters 18A and 18C are presumed to be innovative. This is now expanded to Qualified Biotech Applicants and Qualified Specialist Technology Applicants even when they seek to list under Chapter 8.
- Qualified Biotech Applicants must: (i) operate in the biotech industry, have commercialised at least one Core Product, and have been primarily engaged in its R&D; (ii) have continued R&D of that Core Product in the 12 months prior to listing; and (iii) hold ownership of the relevant IP rights.
- Qualified Specialist Technology Applicants must: (i) be primarily engaged in the R&D of, and have commercialised, a Specialist Technology Product within an acceptable sector; and (ii) meet the R&D expenditure percentage test applicable to Commercial Companies under Chapter 18C.
HKEX also clarified the meaning of sophisticated investor and the external validation rule under the WVR regime. WVR applicants must continue to demonstrate meaningful pre-IPO investment from at least one Sophisticated Investor. HKEX will assess investor sophistication on a case-by-case basis by reference to relevant investment experience, knowledge, expertise, net assets, assets under management, portfolio size, and investment track record, with no explicit exclusions.
B. Issuers Listed Overseas
Qualification requirements for secondary listings
HKEX has streamlined secondary listing pathways by lowering market capitalisation thresholds for both WVR and non-WVR issuers, significantly enhancing Hong Kong’s appeal as a premier venue for overseas-listed companies.
WVR Issuers
Financial eligibility thresholds for secondary listing of an overseas issuer with a WVR structure are now lowered to match those for primary WVR listings as set out above.
Non-WVR issuers
An overseas issuer seeking a secondary listing without a WVR structure on HKEX must satisfy either Criteria A or Criteria B:
- Criteria A:
- (i) A track record of good regulatory compliance of at least five full financial years on a Qualifying Exchange or (only for issuers without a centre of gravity in Greater China) any Recognised Stock Exchange; and
- (ii) a market capitalisation of at least HK$3 billion at the time of listing.
- Criteria B:
- (i) A track record of good regulatory compliance of at least two full financial years on a Qualifying Exchange; and
- (ii) A market capitalisation of at least HK$10 billion at the time of listing.
Under the new amendments, the market capitalisation threshold under Criteria B is lowered from HK$10 billion to HK$6 billion.
C. Initial Listing Requirements and Listing Arrangements
Ownership Continuity and Control
Under the new regime, a mere change in controlling shareholders in the relevant period would not automatically exclude applicants’ eligibility from listing. Issuers will be considered to have satisfied this requirement if it can demonstrate that there was no material change in influence on management and decision-making during the relevant period despite a change in ownership. This proposal grants greater certainty and flexibility for corporate restructurings and ownership changes.
Financial Reporting Standards
To reduce compliance costs for cross-border corporate groups and US-linked issuers seeking a Hong Kong listing, HKEX expanded the usage of US GAAP accounting standards.
Commercialised Biotech Companies and Specialist Technology Companies
Biotech Companies and Specialist Technology Companies (“Eligible Specialist Companies”) can now seek a listing under the applicable specialist chapters even if they satisfy one or more of the Chapter 8 eligibility tests. This means they can still list under the specialist chapters instead of being limited to listing under Chapter 8.
Confidential filing
Confidential filing will be available to all new listing applicants. A new applicant may now choose not to publish its Application Proof (AP) at the time it submits its listing application and would only be required to publish an Overall Coordinator Announcement on the same date as it publishes its Post Hearing Information Pack (PHIP).
Enhanced Return Mechanism
Where HKEX determines that an application is not substantially complete and the application is returned, HKEX will now disclose the identities and roles of all professional parties involved – including sponsors, legal advisers, reporting accountants, auditors, industry consultants, in addition to the reasons for return on the Exchange’s designated website.
Conclusion
The recent HKEX Listing Rule amendments represent a decisive shift toward a more modern, flexible, and internationally competitive listing framework. These reforms will continue to strengthen Hong Kong’s position as a leading global listing venue, applicants considering a listing in Hong Kong in the near future should reassess their listing routes and structuring options in light of the latest amendments.
If you have any questions, please do not hesitate to get in touch.
The information given in this document concerning technical legal or professional subject matter is for guidance only and does not constitute legal or professional advice. Always consult a suitably qualified lawyer on any specific legal problem or matter. Bird & Bird assumes no responsibility for such information contained in this document and disclaims all liability in respect of such information.
For further information, please contact:
David Cheng, Partner, Bird & Bird
